Tesaro (Tesaro) EPS (Diluted) : $-11.86 (TTM As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Tesaro EPS (Diluted)?

Tesaro's Earnings per Share (Diluted) for the three months ended in Sep. 2018 was $-2.49. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was $-11.86.

Tesaro's EPS (Basic) for the three months ended in Sep. 2018 was $-2.49. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2018 was $-11.86.

Tesaro's EPS without NRI for the three months ended in Sep. 2018 was $-2.49. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2018 was $-11.86.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Tesaro EPS (Diluted) Historical Data

The historical data trend for Tesaro's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tesaro EPS (Diluted) Chart

Tesaro Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EPS (Diluted)

Get a 7-Day Free Trial

-2.93

-4.79

-6.29

-7.85

-9.17

Tesaro Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EPS (Diluted)	Get a 7-Day Free Trial															-0.47	-3.35	-2.98	-3.04	-2.49

Competitive Comparison of Tesaro's EPS (Diluted)

For the Biotechnology subindustry, Tesaro's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tesaro's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tesaro's PE Ratio distribution charts can be found below:

* The bar in red indicates where Tesaro's PE Ratio falls into.

Tesaro EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Tesaro's Diluted EPS for the fiscal year that ended in Dec. 2017 is calculated as

Diluted EPS (A: Dec. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-496.126	-	0)	/	54.080
	=	-9.17

Tesaro's Diluted EPS for the quarter that ended in Sep. 2018 is calculated as

Diluted EPS (Q: Sep. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-137.088	-	0)	/	54.957
	=	-2.49

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.86

Tesaro (NAS:TSRO) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Tesaro EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Tesaro's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Tesaro (Tesaro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tesaro Inc (NAS:TSRO) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tesarobio.com

Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Executives

Mary Lynne Hedley	director, officer: President & COO	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Kavita Patel	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Huber Martin H. Jr.	officer: SVP & Chief Medical Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Moulder Leon O Jr	director, officer: Chief Executive Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Timothy R Pearson	officer: Exec. VP, CFO	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Grant C. Bogle	officer: Sr. VP, Chief Commercial Ofc	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Collier Earl M Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Beth C Seidenberg	director
Joseph L Farmer	officer: Sr VP, Gen Counsel & Secretary	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Patrick J Kerins	10 percent owner